Cardiac Biomarkers Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Cardiac Biomarkers Market is Segmented by Biomarker Type (Troponins, Creatine Kinase, and More), Application (Acute Coronary Syndrome, Myocardial Infarction, and More), Location of Testing (Central Laboratory Testing, and More), End-User (Hospitals, Diagnostic Laboratories, and More) and Geography (North America, Europe, Asia-Pacific, and More). The Market and Forecasts are Provided in Terms of Value (USD).

Cardiac Biomarkers Market Size and Share

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Compare market size and growth of Cardiac Biomarkers Market with other markets in Healthcare Industry

Cardiac Biomarkers Market Analysis by Mordor Intelligence

The cardiac biomarkers market size stood at USD 18.91 billion in 2025 and is forecast to reach USD 35.56 billion by 2030, advancing at a 13.46% CAGR. Adoption of high-sensitivity assays, rapid point-of-care platforms and AI-driven decision support systems is accelerating test volumes as health systems pursue earlier rule-out strategies for acute coronary events. Expansion of public- and private-sector proteomics funding is widening the discovery pipeline, while the FDA’s first point-of-care high-sensitivity cardiac troponin approval in 2024 has shortened emergency department rule-out times from one hour to 17 minutes. Demand is further reinforced by the 127.9 million American adults living with cardiovascular disease, equivalent to 48.6% of the population. Meanwhile, Asia-Pacific regulatory modernization is creating attractive reimbursement-linked growth prospects for novel biomarkers and decentralized testing platforms.

Key Report Takeaways

  • By biomarker type, troponins held 59.87% of the cardiac biomarkers market share in 2024, while ischemia-modified albumin is projected to expand at a 14.21% CAGR to 2030.  
  • By application, myocardial infarction led with 40.23% revenue share in 2024; acute coronary syndrome is forecast to grow at a 14.27% CAGR through 2030.  
  • By location of testing, central laboratories accounted for 58.98% share of the cardiac biomarkers market size in 2024, while point-of-care platforms are advancing at a 14.38% CAGR to 2030.  
  • By end user, hospitals commanded 53.88% share in 2024; home healthcare settings record the fastest CAGR at 14.58% through 2030.  
  • By region, North America captured 42.21% of the cardiac biomarkers market share in 2024, yet Asia-Pacific will register the highest CAGR at 14.52% to 2030.  

Segment Analysis

By Biomarker Type: Troponins anchor adoption, novel markers accelerate

Troponins controlled 59.87% of the cardiac biomarkers market in 2024, validating decades of clinical trust in these gold-standard proteins. Segment revenues benefit from the shift to high-sensitivity formats that detect minute myocardial injury within two hours of symptom onset. Conversely, ischemia-modified albumin is expanding at a 14.21% CAGR, reflecting growing recognition that transient coronary vasospasm events demand markers able to capture reversible ischemia that troponin misses.

The cardiac biomarkers market size attributable to troponins reached USD 11.3 billion in 2025. Manufacturers are augmenting assay menus with microRNAs and inflammatory proteins, yet clinical uptake hinges on regulatory clearance and guideline endorsement. Creatine kinase is tapering as high-sensitivity troponins deliver superior specificity, while myoglobin remains a legacy option used primarily for ultra-early triage before troponin rises.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Application: Acute coronary syndrome protocols shape growth

Applications in myocardial infarction generated 40.23% of segment revenue for the cardiac biomarkers market in 2024. Hospitals rely on troponin algorithms to meet door-to-needle targets, a metric directly tied to reimbursement bonuses. Acute coronary syndrome, however, is climbing at a 14.27% CAGR, driven by 0/2-hour rule-out pathways that safely discharge low-risk patients and decrease telemetry bed occupancy.

The cardiac biomarkers market size for acute coronary syndrome is estimated to be underpinned by payer incentives that reward avoidance of unnecessary admissions. Chronic care settings are also expanding use cases; BNP-based management of heart failure reduces readmission penalties under the Medicare Hospital Readmissions Reduction Program, while ASCVD coding requirements integrate biomarker panels into annual risk reviews.

By Location of Testing: Point-of-care transformation intensifies

Central laboratories preserved a 58.98% revenue share in 2024, leveraging high-throughput analyzers and consolidated procurement contracts. Yet point-of-care systems are advancing at a 14.38% CAGR thanks to FDA-cleared platforms delivering high-sensitivity troponin I results in 17 minutes. Emergency physicians value near-patient testing that avoids transport lag, improving adherence to 60-minute turnaround benchmarks.

Point-of-care expansion is further accelerated by acquisition activity; bioMérieux’s EUR 138 million SpinChip purchase adds a 10-minute whole-blood immunoassay cartridge that rivals central-lab precision. Cost of ownership is narrowing as microfluidic manufacturing scales, enabling community hospitals and ambulatory surgery centers to deploy decentralized analyzers without extensive infrastructure.

Cardiac Biomarkers Market: Market Share by Location of Testing
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By End User: Home healthcare emerges as a catalyst

Hospitals commanded 53.88% of demand in 2024, yet home healthcare settings are projected to deliver a 14.58% CAGR through 2030. Portable saliva-based sensors now quantify galectin-3 and S100A7 within 15 minutes at USD 3.00 unit cost, supporting at-home monitoring for chronic cardiac patients. Integration of Bluetooth-enabled cartridges into telehealth apps allows clinicians to trend serial values remotely.

The cardiac biomarkers market size allocated to home use could surpass USD 5 billion by 2030, propelled by payer support for remote physiologic monitoring codes and patient preference for in-home sampling. Diagnostic laboratories retain relevance for complex multiplex panels, while ambulatory clinics leverage handheld analyzers for perioperative risk stratification.

Geography Analysis

North America captured 42.21% of the cardiac biomarkers market in 2024, supported by well-funded payers, mature laboratory networks and guideline alignment that validates high-sensitivity assays. CMS coding updates further entrench biomarker requirements within preventative cardiology workflows. The region’s testing volumes will keep pace with population aging, yet pricing pressure from bundled payment models is likely to temper revenue expansion.

Europe follows as the second-largest region, with public healthcare systems anchoring troponin adoption for rapid rule-out protocols. Implementation of the In-Vitro Diagnostic Regulation increases compliance costs but also elevates trust in clinically validated assays, reinforcing adoption across Germany, France and the United Kingdom. Market momentum will hinge on balancing reimbursement ceilings with cost-effective multiplex panels that reduce downstream imaging utilization.

Asia-Pacific is the fastest-growing territory, poised to post a 14.52% CAGR. Japan’s USD 40 billion medical device sector is already embracing high-sensitivity troponin and BNP testing, aided by PMDA expedited review channels. China’s National Medical Products Administration has approved 61 innovative diagnostics in 2023, signaling a friendlier path for foreign and domestic biomarker vendors. Rising cardiovascular prevalence, coupled with government insurance expansion, drives demand for decentralized point-of-care solutions in secondary hospitals.

Middle East & Africa and South America represent emerging catch-up markets. Gulf Cooperation Council states are investing in tertiary cardiac centers equipped with high-throughput analyzers, while Brazil and Mexico roll out universal health coverage pilots that reimburse early myocardial infarction diagnostics. Suppliers able to deliver affordable, stable ambient-temperature reagents will gain share as freight and cold-chain constraints persist.

Cardiac Biomarkers Market CAGR (%), Growth Rate by Region
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

The cardiac biomarkers market remains moderately fragmented, with leading companies carving out niches through acquisitions, assay innovation and digital integration. bioMérieux’s SpinChip purchase consolidates near-patient testing assets and accelerates time-to-result to 10 minutes for whole-blood immunoassays, directly challenging Abbott’s i-STAT and Roche’s cobas h 232 portfolios. Siemens Healthineers differentiates via prognostic claims on its high-sensitivity troponin I, extending utility beyond diagnosis into one-year risk stratification.

Thermo Fisher Scientific’s Olink acquisition positions it at the discovery frontier, leveraging proximity extension assays to uncover novel proteins with potential cardiac relevance. Beckman Coulter and Ortho Clinical Diagnostics focus on menu breadth inside core labs, bundling cardiac markers with infectious disease panels for automated analyzers to protect reagent annuities. Start-ups such as RCE Technologies pursue continuous, wearable transdermal monitoring that could redefine chronic care paradigms once regulatory hurdles are cleared.

Competitive differentiation increasingly rests on embedded analytics. Vendors are integrating cloud dashboards that plot serial troponin curves against machine-learning risk scores, delivering actionable flags to physicians within electronic health records. Interoperability and cybersecurity are becoming procurement gate-checks as health systems align with zero-trust frameworks. Companies offering subscription-based decision-support modules may capture annuity revenue even as reagent prices face downward pressure.

Cardiac Biomarkers Industry Leaders

  1. Abbott Laboratories

  2. Becton, Dickinson and Company

  3. BioMérieux

  4. Bio-Rad Laboratories, Inc.

  5. Danaher Corporation

  6. *Disclaimer: Major Players sorted in no particular order
Cardiac Biomarkers Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • January 2025: bioMérieux completed acquisition of SpinChip Diagnostics for EUR 138 million, adding a 10-minute whole-blood immunoassay platform slated for launch in 2026.
  • June 2024: Siemens Healthineers added the NT-proBNP II assay to its Atellica Solution, enabling labs to choose between BNP and NT-proBNP for heart-failure evaluation.
  • April 2024: RCE Technologies reported first-in-human pilot results for its Infrasensor wearable that continuously tracks transdermal cardiac biomarkers.
  • March 2024: Diasorin’s LIAISON PLEX platform received FDA clearance, broadening U.S. access to advanced cardiac biomarker panels.

Table of Contents for Cardiac Biomarkers Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing prevalence of cardiovascular diseases
    • 4.2.2 Technological advances in high-sensitivity assays
    • 4.2.3 Growing public- & private-sector R&D funding
    • 4.2.4 Expansion of multiplex panels for early rule-out protocols
    • 4.2.5 AI-enabled predictive analytics integrating troponins with EHRs
    • 4.2.6 Adoption of at-home finger-stick cardiac biomarker kits
  • 4.3 Market Restraints
    • 4.3.1 Stringent regulatory frameworks
    • 4.3.2 Reimbursement erosion from bundled-payment models
    • 4.3.3 Analytical variability of novel POC devices
    • 4.3.4 Limited specificity generating false-positive results
  • 4.4 Regulatory Landscape
  • 4.5 Technological Outlook
  • 4.6 Porters Five Forces Analysis
    • 4.6.1 Bargaining Power of Suppliers
    • 4.6.2 Bargaining Power of Buyers/Consumers
    • 4.6.3 Threat of New Entrants
    • 4.6.4 Threat of Substitute Products
    • 4.6.5 Intensity of Competitive Rivalry

5. Market Size & Growth Forecasts (Value, USD)

  • 5.1 By Biomarker Type
    • 5.1.1 Troponins
    • 5.1.2 Creatine Kinase
    • 5.1.3 Myoglobin
    • 5.1.4 Ischemia-Modified Albumin
    • 5.1.5 Other Biomarker Type
  • 5.2 By Application
    • 5.2.1 Acute Coronary Syndrome
    • 5.2.2 Myocardial Infarction
    • 5.2.3 Congestive Heart Failure
    • 5.2.4 Atherosclerosis
    • 5.2.5 Other Applications
  • 5.3 By Location of Testing
    • 5.3.1 Point-of-care Testing
    • 5.3.2 Central Laboratory Testing
  • 5.4 By End-user
    • 5.4.1 Hospitals
    • 5.4.2 Diagnostic Laboratories
    • 5.4.3 Ambulatory Surgery Centers & Clinics
    • 5.4.4 Home Healthcare Settings
    • 5.4.5 Others
  • 5.5 By Geography
    • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
    • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
    • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
    • 6.3.1 Abbott Laboratories
    • 6.3.2 F. Hoffmann-La Roche AG
    • 6.3.3 Siemens Healthineers
    • 6.3.4 Danaher Corp. (Beckman Coulter)
    • 6.3.5 Thermo Fisher Scientific
    • 6.3.6 bioMerieux SA
    • 6.3.7 QuidelOrtho Corp.
    • 6.3.8 Randox Laboratories Ltd.
    • 6.3.9 Bio-Rad Laboratories Inc.
    • 6.3.10 Becton, Dickinson and Company
    • 6.3.11 PerkinElmer Inc.
    • 6.3.12 DiaSorin SpA
    • 6.3.13 Tosoh Corp.
    • 6.3.14 Trinity Biotech plc
    • 6.3.15 Shenzhen Mindray Bio-Medical Electronics
    • 6.3.16 Werfen SA
    • 6.3.17 LSI Medience Corp.
    • 6.3.18 LumiraDx Ltd.
    • 6.3.19 Response Biomedical Corp.

7. Market Opportunities & Future Outlook

  • 7.1 White-space & Unmet-need Assessment
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global Cardiac Biomarkers Market Report Scope

As per the scope of the report, cardiac biomarkers are of great importance in the timely and accurate diagnosis and management of acute coronary syndrome, as well as the prognosis. The Cardiac Biomarkers Market is segmented by Type (Creatine Kinase, Troponins, Myoglobin, Ischemia Modified Albumin, and Other Types), Application (Congestive Heart Failure, Acute Coronary Syndrome, Myocardial Infarction, Atherosclerosis, and Other Applications), Location of Testing (Point-of-Care Testing and Laboratory Testing), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers market sizes and forecasts in terms of value (USD million) for all the above segments.

By Biomarker Type Troponins
Creatine Kinase
Myoglobin
Ischemia-Modified Albumin
Other Biomarker Type
By Application Acute Coronary Syndrome
Myocardial Infarction
Congestive Heart Failure
Atherosclerosis
Other Applications
By Location of Testing Point-of-care Testing
Central Laboratory Testing
By End-user Hospitals
Diagnostic Laboratories
Ambulatory Surgery Centers & Clinics
Home Healthcare Settings
Others
By Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
By Biomarker Type
Troponins
Creatine Kinase
Myoglobin
Ischemia-Modified Albumin
Other Biomarker Type
By Application
Acute Coronary Syndrome
Myocardial Infarction
Congestive Heart Failure
Atherosclerosis
Other Applications
By Location of Testing
Point-of-care Testing
Central Laboratory Testing
By End-user
Hospitals
Diagnostic Laboratories
Ambulatory Surgery Centers & Clinics
Home Healthcare Settings
Others
By Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

What is the current size of the cardiac biomarkers market?

The cardiac biomarkers market size stands at USD 18.91 billion in 2025 and is projected to reach USD 35.56 billion by 2030.

Which biomarker segment dominates the cardiac biomarkers market?

Troponins dominate, accounting for 59.87% share of 2024 revenues, thanks to guideline endorsement for myocardial infarction diagnosis.

How fast is the point-of-care segment growing?

Point-of-care cardiac biomarker testing is expanding at a 14.38% CAGR through 2030, driven by 17-minute high-sensitivity troponin assays.

Why is Asia-Pacific the fastest-growing region?

Regulatory modernization in Japan and China, combined with rising cardiovascular incidence, is propelling a 14.52% regional CAGR.

What impact will bundled payments have on test utilization?

Bundled payment models reduce per-test reimbursement, compelling providers to prove that biomarker-guided pathways cut readmissions and total episode costs.

Which recent acquisition reshaped the competitive landscape?

BioMérieux’s EUR 138 million takeover of SpinChip Diagnostics in 2025 strengthened its near-patient testing portfolio with a 10-minute immunoassay platform.

Page last updated on: June 25, 2025

Cardiac Biomarkers Market Report Snapshots